Hepatitis B (krónikus): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 4
• PD-L1 2
• TP53 0
• STAT3 0
• STING 0
• CD19 0
• TNF 0
• AMPK 0
• JAK 0
• mTOR 0
• CD20 0
• EGFR 0
• ERK 0
• GPC3 0
• HIF-1 0
• IL-1 0
• IL-6 0
• PI3K 0
• PPAR 0
• TFEB 0
• ABL1 0
• AKT 0
• BCL-2 0
• CTLA-4 0
• G6PD 0
• HMGB1 0
• HSP90 0
• IL-17 0
• MYC 0
• NRF2 0
• PARP 0
• VEGF 0
• ALK 0
• AQP4 0
• ARID1A 0
• CCR5 0
• CD33 0
• CD38 0
• CD40 0
• CTNNB1 0
• FAK 0
• FGFR 0
• HDAC 0
• IL-23 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MAPK 0
• METTL3 0
• MMP-9 0
• NLRP3 0
• NOTCH1 0
• PKM2 0
• PNPLA3 0
• PRMT5 0
• PSMA 0
• PTEN 0
• SGLT2 0
• TERT 0
• TIM-3 0

8+ intézményből 8, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, Egyesült Államok· 18 735 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAID · F31

  The Bifunctional Role of Interleukin-1β in Modulating Hepatitis B Virus Replication and Host Defense During HIV/HBV Coinfection

  Emory University· Atlanta, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NHLBI · R01

  Transfusion transmitted infections and pathogen reduction technology.

  Johns Hopkins University· Baltimore, Egyesült Államok· 1 084 885 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NIBIB · N02

  RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - VALIDATION CENTER - Hep C

  Emory University· Atlanta, Egyesült Államok· 5 119 273 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIAID · R01

  Immune protection against H5N1 influenza virus infection and transmission

  Washington University· Saint Louis, Egyesült Államok· 765 798 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding Immune Aging in Chronic Hepatitis B (DECAGE)

  Universita Vita-Salute San Raffaele· Milano, Olaszország· EU contribution 209 483 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Implementation of an Integrated Digital Health System for Infectious Diseases in Maternal and Child Health In East Africa (LINDA-FAMILIA)

  University College Cork - National University of Ireland, Cork· Cork, Írország· EU contribution 4 998 563 EUR· until 2029. júl.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Innovative Point of Care for combined screening of Infectious diseases: application to Prevention of Mother to Child Transmission (MAGFA)

  Magia Diagnostics· Echirolles, Franciaország· EU contribution 5 078 816 EUR· until 2027. dec.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B (EUCLIDEAN)

  Universita Vita-Salute San Raffaele· Milano, Olaszország· EU contribution 2 500 000 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D (D-SOLVE)

  Medizinische Hochschule Hannover· Hannover, Németország· EU contribution 6 754 010 EUR· until 2027. szept.· 5 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 264 running projects, newest first. Listed amounts together: 216,4 M USD + 32,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

  NCT05275023· Janssen Research & Development, LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 12
• Organoids 3
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 23
• Gene Expression Profiling 26
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 10
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 4
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 2
• Magnetic Resonance Imaging 22
• Machine Learning 38
• Deep Learning 6
• Cohort Studies 63
• Genome-Wide Association Study 12

• Anti-Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH-B Study.

  J Viral Hepat, 2026. dec.

• Becoming Physically Active and Risks of Mortality and Liver-Related Events in Adults With Chronic Hepatitis B: A Nationwide Cohort Study.

  J Viral Hepat, 2026. nov.

• Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland.

  Vaccine, 2026. okt.

• Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023.

  Cancer Causes Control, 2026. okt.

• Peripheral blood inflammatory indices may predict distinct serologic patterns of hepatitis B virus infection: a large hospital cohort study.

  Lab Med, 2026. okt.

• White Blood Cell to HDL-C Ratio and Sarcopenia: A Dual-Cohort Analysis Including Exploratory Insights on Hepatitis B History.

  Geriatr Gerontol Int, 2026. okt.

• High Treatment Adherence Is Associated With Lower Observed HCC Risk in Patients With Chronic Hepatitis B and Cirrhosis: A Nationwide Claims-Based Cohort Study.

  J Med Virol, 2026. okt.

• SEROLOGICAL CLEARANCE OF HBSAG IN CHRONIC HEPATITIS B: EXPERIENCE IN A UNIVERSITY HOSPITAL.

  Arq Gastroenterol, 2026. szept.

• The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD.

  J Gastroenterol Hepatol, 2026. szept.

• Dynamics of Anti-HBc Serology During Anti-CD20 Therapy: Incidence, Timing, and Predictors of Anti-HBc Seroclearance in a Retrospective Cohort.

  Medicina (Kaunas), 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.